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E-mail address: eferro@usp.br (E.S. Ferro).Mammalian cells have a large number of intracellular peptides that are generated by extralysosomal
proteases. In this study, the enzymatic activity of thimet oligopeptidase (EP24.15) was inhibited in
human embryonic kidney (HEK) 293 cells using a speciﬁc siRNA sequence. The semi-quantitative
intracellular peptidome analyses of siRNA-transfected HEK293 cells shows that the levels of speciﬁc
intracellular peptides are either increased or decreased upon EP24.15 inhibition. Decreased
expression of EP24.15 was sufﬁcient to potentiate luciferase gene reporter activation by isoprotere-
nol (1–10 lM). The protein kinase A inhibitor KT5720 (1 lM) reduced the positive effect of the
EP24.15 siRNA on isoproterenol signaling. Thus, EP24.15 inhibition by siRNA modulates the levels
of speciﬁc intracellular peptides and isoproterenol signal transduction.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Thimet oligopeptidase (EC3.4.24.15; EP24.15) is a characteristic
metalloendopeptidase with a HEXXH catalytic motif containing
zinc that belongs to the family of M3 metallopeptidases. EP24.15
is designated as an oligopeptidase, as it only degrades short pep-
tides (5–17 amino acids). Because EP24.15 is activated by thiol
compounds, it is referred to as thimet (for thiol-activated metallo-
protease) [1,2]. Maximal enzymatic activity of EP24.15 is main-
tained by partial S-glutathionylation, which is a mechanism that
regulates protein oligomerization and enzymatic activity [3].
Despite being described as a secreted neuropeptide-metabolizing
enzyme [4], experimental evidences accumulated over the past
years shows that EP24.15 is predominately expressed in the cyto-
plasm and nucleus of neuronal cells [5]. Several studies have sug-
gested intracellular functions for EP24.15 [6–9]. In macrophages,
EP24.15 inhibition reduces the presentation of heat shock protein
65 antigens associated with the major histocompatibility complex
class I (MHC-I) while the addition of recombinant EP24.15 increases
hsp65 presentation [9]. EP24.15 was also shown to contribute to C-
terminal trimming of antigenic peptides, after the processing activ-
ity of the proteasome [6].chemical Societies. Published by E
ll Biology and Development,
s 1524, Sala 431, São PauloPoint mutations in EP24.15 leading to inactivation of its cata-
lytic properties were generated, and the inactive form of EP24.15
was used in a substrate capture assay that identiﬁed several novel
peptides [10]. Several of these intracellular peptides isolated from
the rat brain using the inactive EP24.15 substrate capture assay
actively affected the signal transduction of G protein-coupled
receptors (GPCR) when introduced into CHO-S-AT1 and HEK293
cells [11]. Overexpression of EP24.15 in these cells also alters sig-
nal transduction induced by GPCR agonists, such as angiotensin II
and isoproterenol [11], and leads to a marked alteration of the
intracellular peptide content [12]. The mechanisms by which
EP24.15 and/or its peptide substrates/products exert their effects
on intracellular signal transduction of GPCRs are not fully under-
stood; however, peptides that alter the signal transduction of
GPCRs have been shown to bind to speciﬁc proteins involved in cell
signaling [11]. Recently, intracellular peptides have been shown to
modulate protein–protein interactions, which could be a mecha-
nism related to their physiological function [13]. The overexpres-
sion of EP24.15 in HEK293 cells transfected with the bradykinin
B2 receptor markedly changes the production of inositol phosphate
and increases the levels of intracellular free calcium [14]. Thus,
EP24.15 intracellular function and intracellular peptides may be
related to signal transduction.
In this study, we inhibited the expression of EP24.15 in HEK293
cells using siRNAs and examined changes in the intracellular
peptide content and isoproterenol GPCR signal transduction in a
luciferase gene reporter assay.lsevier B.V. All rights reserved.
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2.1. Cell culture and EP24.15 suppression
HEK293 cells were cultured in Dulbecco’s modiﬁed Eagle’s med-
ium (DMEM) containing 10% fetal bovine serum, penicillin (100 U/
ml) and streptomycin (100 lg/mL) (Life Technologies Co., Carlsbad,
CA, USA) and were incubated at 37 C in a humidiﬁed atmosphere
containing 5% CO2 and 95% air. The suppression of EP24.15 expres-
sion was performed using RNA interference (siRNA) in HEK293
cells. siRNAs targeting human EP24.15 were purchased commer-
cially (IDT, Integrated DNA Technologies Inc., Coralville, IA, USA)
as a kit that contained three target sequences to EP24.15. We chose
the sequence responsible for the greatest inhibition of EP24.15
(Supplemental Material) and also used a control sequence (scram-
bled) that contains no homology to any existing protein. Brieﬂy,
HEK293 cells were plated in 35 mm plates (0.4  106 cells/well)
overnight and were transiently transfected with siRNA sequences
using Lipofectamine RNAiMax (Life Technologies Co., Calsbad,
CA, USA). Enzymatic activity assays and western blot analysis were
performed as previously described in our laboratory [15,16] to ver-
ify the time at which there was the greatest decrease in EP24.15
expression.
2.2. EP24.15 enzymatic assay and Western blot
The enzymatic activity of EP24.15 was determined in triplicate
using a continuous assay with a quenched ﬂuorescent substrate
(QFS;7-methoxycoumarin-4-acetyl-P-L-G-P-dK-(2,4-dinitrophenyl)
as previously described [17]. The EP24.15 speciﬁc inhibitor N-[1-
(R,S)-carboxy-3-phenylpropyl]-Ala-Aib-Tyr-p-aminobenzoate (JA2;
1 lM)was used to discern the peptidolytic activity attributed exclu-
sively to EP24.15 [18]. The results were expressed as arbitrary units
of ﬂuorescence (UAF) per minute normalized by protein concentra-
tion. Western blotting was conducted using anti-EP24.15-speciﬁc
antiserum (1:3000; Proteimax Biotech, São Paulo, SP, Brazil) diluted
in 25 mMTris–HCl, pH 7.4 and 125 mMNaCl containing 0.1% Tween
20 (TTBS) in 5% fat-free dry milk with a 2-h incubation time at room
temperature. Goat anti-rabbit IgG conjugated to peroxidase (1:2000;
GE Healthcare Co., Waukesha, WI, USA) was used as the secondary
antibody. Blots were developed using the Super Signal Chemilumi-
nescent Substrate and high sensitivity photographic ﬁlm (Thermo
Scientiﬁc Inc., Rockford, IL, USA).
2.3. Peptide extraction, quantiﬁcation and isotopic labeling
Peptide extraction from HEK293 cells and quantiﬁcation was
conducted as previously described [12,19]. The peptide quantiﬁca-
tion reaction was performed at pH 6.8 to ensure that only the ami-
no groups of peptides but not free amino acids react with
ﬂuorescamine [20]. The isotopic labeling of peptides for semi-
quantiﬁcation was performed as originally described [21–24].
2.4. Liquid chromatography and tandem mass spectrometry
(LC–MS/MS) analyses
LC–MS/MS experiments were performed on a Synapt G1 mass
Spectrometer (Waters Co., Milford, MA, USA). The peptide mixture
was desalted on line for 15 min using a Symmetry C18 trapping
column (5 lm particles, 180 lm inner diameter, 20 mm length;
Waters Co., Milford, MA, USA). The mixture of trapped peptides
was subsequently separated by elution with a water/acetonitrile/
0.1% formic acid gradient through a BEH 130-c18 column (1.7 lm
particles, 100 lm inner diameter, 100 mm length; Waters Co., Mil-
ford, MA, USA). Data were acquired in data-dependent mode andmultiple-charged protonated peptides generated by electrospray
ionization (ESI) were automatically mass selected and dissociated
in MS/MS by 10–30-eV collisions with argon. Typical LC and ESI
conditions consisted of a ﬂow rate of 600 nL/min, capillary voltage
of 3.5 kV, block temperature of 100 C, and cone voltage of 100 V.
2.5. MS data analyses
To identify peptides, the raw data ﬁles were converted to a peak
list format (mgf) by Mascot Distiller version 2.1.1 (Matrix Science
Ltd., London, UK) and analyzed using the search engine MASCOT
version 2.2 (Matrix Science Ltd.). Selected variable modiﬁcations
on lysine residues (K) and the N-terminus (N-term) included TMAB
GIST-Quat (K) and GIST-Quat (N-term), for labels with nine hydro-
gen, and GIST Quat: 2H (9) (K) and GIST-Quat: 2H (9) (N-term), for
labels with nine deuterium. The NCBI database (from 01 Jul 2009;
9,298,190 sequences) was used for searches with taxonomy Homo
sapiens, ‘‘no enzyme’’, and 0.1 Da of mass tolerance for MS and MS/
MS precursor ions. Mascot searches were followed bymanual inter-
pretation to eliminate false positives. Several criteria were used to
accept or decline the peptides that were identiﬁed by MASCOT as
follows: (1) the majority (>80%) of the major MS/MS fragment ions
matched predicted a, b, or y ions or parent ions with loss of trimeth-
ylamine; (2) a minimum of ﬁve fragment ions matched b or y ions;
(3) the number of tags incorporated into the peptide matched the
number of free amines (N terminus and side chains of Lys). Quanti-
ﬁcation was performed by measuring the ratio of peak intensity for
the various TMAB-labeled peptide pairs in the MS spectra. For this
analysis, the monoisotopic peak and the peaks containing one or
two atoms of 13C were used. Multiple scans of the MS spectra were
combined prior to quantiﬁcation.
2.6. Luciferase reporter gene assay
To analyze the possible effects of the peptides on GPCR intracel-
lular signaling, a reporter gene construct composed of three copies
of the IL-6 multiple response element in tandem with a cAMP-
responsive element (CRE) that drives luciferase expression in
response to Gi, Gs, or Gq stimulation was constructed as previously
described [11]. To assess promoter activity, a dual luciferase repor-
ter assay system (Promega Co., Fitchburg, WI, USA) was used. In
brief, 24 h after the siRNA transfection, HEK293 cells were tran-
siently transfected with pEGFP (1 lg; codes for the pGL3-CRE-
MRE promoter luciferase construct) and the pRL-CMV plasmid
(16 ng; encodes the Renilla luciferase and is used to normalize
transfection efﬁcacy) using HEKFectin™ Cell Line Speciﬁc Lipid
(Bio-Rad Laboratories Inc., Hercules, CA, USA) for 6 h. Transfected
cells were incubated in Dulbecco’s modiﬁed Eagle’s medium con-
taining 10% fetal bovine serum overnight and were subsequently
seeded (0.1  106 cells/well) onto a 96-well plates. Forty-eight
hours after transfection, HEK293 cells were stimulated with either
1 or 10 lM isoproterenol for 6 h at 37 C. Fireﬂy and Renilla lucifer-
ase activities in cell lysates were measured using a LMax lumino-
meter (Molecular Devices, LLC., Sunnyvale, CA, USA) according to
the manufacturer’s instructions. The relative luciferase activity
was calculated by normalizing ﬁreﬂy luciferase activity to Renilla
luciferase.
3. Results
One of the three siRNA sequences initially evaluated in this
study was able to cause a higher reduction on the EP24.15
enzymatic activity and was selected for further experiments
(Supplemental Fig. 1). The HEK293 cells transfected with EP24.15
siRNA showed an approximately 75% reduction of EP24.15
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fected with the control siRNAs containing no homology to any
existing protein (scrambled siRNA; Fig. 1A). In western blot assays,
EP24.15 immunoreactivity was absent in cells transfected with
EP24.15 siRNA (Fig. 1B). The slight discrepancy between the degree
of siRNA-mediated inhibition of EP24.15 expression (100%) and
activity (75%) may be related to the higher sensitivity of the enzy-
matic assays.
HEK293 cells transfected with EP24.15 siRNA (Fig. 1) were sub-
sequently used in mass spectrometry experiments. A total of 113
distinct peptides could be reproducibly detected in all three exper-
iments, while the amino acid sequence of 53 peptides were identi-
ﬁed after MS/MS sequencing analysis using the MASCOT search
program followed by manual interpretation of the respective spec-
tra. Manual interpretation of the Mascot search results was neces-
sary because the program does not consider the trimethylamine
lost from the parent ion, and these ions are often the major ions
in the spectra. Fig. 2 shows a representative MS/MS spectrum used
in the analysis of the 3+ ion with an m/z of 502.74 for the peptide
from heat shock 10-kDa protein. In addition to many fragments
identiﬁed as a, b, or y ions, there were two additional intense frag-
ments not identiﬁed by Mascot. The 651.38m/zwith 2+ represents
the parent ion with the trimethylamine and the 480.70 and
457.32m/z fragments represent the parent ion lacking one and
two TMAB, respectively. The peptides identiﬁed here ranged in size
from 7 to 22 amino acids and were derived from 21 different pro-
teins. Approximately half of the peptides identiﬁed here have been
identiﬁed in previous peptidomic studies using HEK293 cells
[12,25,26], further validating the present analyses.
Quantitative analyses were performed, and the relative peptide
levels were quantiﬁed in each LC/MS runs by measurement of the
peak intensities for each isotopic form detected in the MS spectra.
For this analysis, the intensity of the monoisotopic peak and theFig. 1. Effect of siRNA on the expression and enzymatic activity of EP24.15 in HEK293
(control). Enzymatic activity and western blot assays were performed to conﬁrm that cell
assay, showed a signiﬁcant decrease in EP24.15 expression. (A) EP24.15 enzymatic act
fraction of QFS hydrolyzing activity. Activity was inhibited by approximately 75% in cells
comparisons were performed using analysis of variance (ANOVA) followed by the Tukey
EP24.15 siRNA compared with cells transfected with scrambled siRNA. The experiments
from cells transfected with EP24.15 siRNA were separated by SDS–PAGE on an 8% polyac
rabbit antiserum against EP24.15 (1:3000). After incubation with an anti-rabbit IgG-hor
bands were visualized by chemiluminescence.peak containing one atom of 13C were measured. In this analysis,
about half of the peptides identiﬁed had altered levels in cells
transfected with siRNA to suppress EP24.15 expression compared
with control cells (Supplemental Table 1). Twenty peptides were
increased in the experimental samples (ratioP 1.80) and may rep-
resent substrates of the enzyme (Fig. 3, A, D and G). Six peptides
decreased in the experimental samples (ratio 6 0.70) and may rep-
resent products of this enzyme (Fig. 4, B, E and H). Eighty-seven
peptides were considered unchanged (ratios between 0.7 and
1.80) and thus are unlikely to serve as substrates or products of
EP24.15 (Fig. 3, C, F and I). For all of these analyses, the forward
and reverse labeling generally produced similar results (Fig. 3).
The variations between the triplicates are shown in Supplemental
Table 1.
In addition, a luciferase gene reporter assay was employed to
analyze the effects of EP24.15 inhibition on isoproterenol signal
transduction (Fig. 4; Supplemental Fig. 2). It has been previously
shown that HEK293 cells endogenously express the b2-adrenergic
receptors coupled to Gs proteins and upon stimulation activate
adenylate cyclase to raise intracellular cAMP levels and activate
protein kinase A, as well as other downstream molecules [27,28],
which results in increased luciferase expression through multiple
response elements in the gene reporter assays [11]. HEK293 cells
were transfected with scrambled siRNA, EP24.15 siRNA or no
siRNA (mock). After 24 h, the cells were transfected with the lucif-
erase plasmids (pEGFP coding for the pGL3-CRE-MRE promoter
luciferase construct and the pRL-CMV plasmid). The cells were
treated with the b-adrenergic agonist isoproterenol 72 h after the
transfection with siRNA. In all experiments, a signiﬁcant increase
in luciferase activity was observed following stimulation of
HEK293 cells with either 1 or 10 lM isoproterenol (Supplemental
Fig. 2). HEK293 cells transfected with EP24.15 siRNA exhibited
additional increase in luciferase activity that was statistically sig-cells. Cells were transiently transfected with EP24.15 siRNA or scrambled siRNA
s transfected with EP24.15 siRNA, which would later be used for mass spectrometry
ivity was determined using a continuous assay and is shown as the JA2-sensitive
that were transfected with EP24.15 siRNA compared to scrambled siRNA. Statistical
test. p < 0.0001 (⁄⁄⁄) indicate a signiﬁcant difference between cells transfected with
were performed in triplicate. (B) Crude cell extracts (100 lg) from control cells and
rylamide gel, transferred to nitrocellulose membranes, and incubated with speciﬁc
seradish peroxidase-conjugated secondary antibody (1:3000), the immunoreactive
Fig. 2. Representative peptide sequencing by ESI-MS/MS. MS/MS analysis of the peptide KVGDKVLLPE 3+ ion with an m/z of 502.74 that eluted from the reverse-phase
column at 16.7 min and was derived from Heat shock 10 kDa protein 1 (monoisotopic mass of the unprotonated and untagged peptide = 1096.65 Da) is shown. This peptide
represents the D9-TMAB-labeled peptide shown in Fig. 4, A, D and G. After collision-induced dissociation, a, b, and y fragments that contain TMAB tags lost 68 Da (due to
neutral loss of (C2H3)3 N from the tag). In addition, the parent ion [M] also shows neutral loss of 136 Da (2  68 Da) to produce the 3+ ion withm/z = 457.32 and neutral loss of
68 Da to produce the 3+ ion with m/z = 480.03. b32 + 0 = b32+  H2O.
3290 L.C. Russo et al. / FEBS Letters 586 (2012) 3287–3292niﬁcant compared with mock or scrambled siRNA-transfected con-
trols (Supplemental Fig. 2). The presence of the protein kinase
inhibitor KT5720 (1 lM) signiﬁcantly reduced the stimulating
effects of the isoproterenol treatment on the luciferase activity,
both in EP24.15 siRNA and scrambled siRNA cells (Fig. 4).
4. Discussion
Endogenous intracellular peptides have now been described in
different human cell lines and in mouse brain tissue [12,25,26].
Although the cellular function of these peptides has not been
well-established, evidence suggests that they may play a role in
GPCR signal transduction [11], insulin-induced glucose uptake
[29,30] and protein–protein interaction [13]. The metabolism of
these intracellular peptides has recently been examined and stud-
ies suggest that both oligopeptidase EP24.15 [12] and the protea-
some [25] can regulate speciﬁc intracellular peptides in HEK293
cells. In this study, we have shown that EP24.15 enzymatic activity
can be inhibited by a speciﬁc siRNA, which, in parallel, changed the
levels of speciﬁc intracellular peptides and potentiated the stimu-
latory effects of isoproterenol on GPCR signal transduction.
Previous studies have shown that oligopeptides isolated from
rat brain tissue using the inactive EP24.15 and introduced into
CHO-S or HEK293 cells are capable of potentiating both angioten-
sin II and isoproterenol signal transduction [11]. EP24.15
overexpression decreased both angiotensin II and isoproterenolsignal transduction, suggesting a physiological signiﬁcance for
these original ﬁndings. The mechanism by which intracellular pep-
tides modulate GPCR signaling appears to involve their ability to
interact with EP24.15 and other speciﬁc proteins [11]. However,
the direct use of intracellular peptides for therapeutic purposes
can be challenging, as the internalization of peptides or protein
into cells is not a trivial task. Conversely, the use of siRNA is con-
sidered a promising therapeutic option for the treatment of a vari-
ety of diseases, including genetic and viral diseases, as well as
cancer. RNA interference (RNAi) is a post-transcriptional gene
silencing mechanism that involves the degradation of messenger
RNA in a highly sequence-speciﬁc manner. Double-stranded small
interfering RNA (or simply siRNA), consisting of 21–25 nucleotides,
can induce RNAi and inhibit the expression of target proteins.
Therefore, siRNA therapeutics represent a fundamental new way
to treat human disease by addressing targets that are otherwise
‘undruggable’ with existing treatments. The discovery of long dou-
ble-stranded RNA-mediated RNAi in the worm [31] and the subse-
quent demonstration that RNAi, mediated by siRNA, operates in
mammalian cells, sparked an explosion of research to uncover
new mechanisms of gene silencing, which revolutionized our
understanding of endogenous mechanisms of gene regulation
and provided powerful new tools for biological research and drug
discovery [32]. From the ﬁrst in vivo evidence of RNAi-based ther-
apeutic efﬁcacy in an animal disease model in 2003 [33], the pace
of drug development has been rapid. Three Phase I studies to inves-
Fig. 3. Representative MS spectras of TMAB-labeled peptide extracts from cells transfected with EP24.15 siRNA (experimental) or SCB siRNA (control). (A, D and G) MS spectra
of the peptide fragment from heat shock 10-kDa protein 1, subsequently identiﬁed by MS/MS with the peptide sequence KVGDKVLLPE; this peptide was elevated in
experimental samples relative to control samples and was considered a optimal substrate of EP24.15. (B, E and H) MS spectra of a peptide decreased in experimental samples
and therefore was considered a product of EP24.15. This peptide was not identiﬁed by MASCOT and manual sequencing. (C, F and I) MS spectra of the peptide fragment from
Histidine triad nucleotide-binding protein 1 identiﬁed as Ac-ADEIAKAQVAR. This peptide was not altered between experimental samples and control samples.
Fig. 4. EP24.15 siRNA activation of isoproterenol signal transduction is inhibited by the protein kinase inhibitor KT5720. HEK293 cells were transfected with a siRNA control
sequence (scrambled), which contains no homology to any existing protein (scrambled siRNA) or with a siRNA sequence for suppression of EP24.15 (EP24.15 siRNA). After
24 h, cells were transfected with the luciferase plasmid vectors, as detailed in ‘‘Section 2’’. After 48 h, cells were stimulated with 1 lM isoproterenol, in the presence or
absence of 1 lM KT5720, for 20 min, and luciferase activity was subsequently measured after 6 h. While all cells showed increased luciferase activity when stimulated with
isoproterenol, the cells with decreased expression of EP24.15 (EP24.15 siRNA) showed a larger increase of luciferase activity when compared with scrambled siRNA cells
(#p < 0.001; unpaired t test). The protein kinase inhibitor KT5720 signiﬁcantly decreased the isoproterenol effect on luciferase activity both in EP24.15 siRNA and scrambled
siRNA treated cells (⁄⁄⁄p < 0.001; ⁄p < 0.05).
L.C. Russo et al. / FEBS Letters 586 (2012) 3287–3292 3291tigate RNAi-based drugs for age-related macular degeneration
(AMD), a leading cause of blindness, and for respiratory syncytial
virus (RSV), the leading cause of pediatric hospitalizations in the
United States, have already been completed without unfavorable
toxicity [34]. Several types of chemically modiﬁed siRNA have beenproduced and investigated to improve in vivo stability; these stud-
ies have involved modiﬁcation of the siRNA backbone, the sugar
moiety, and the nucleotide bases of antisense and/or sense strands
[35]. Therefore, it is exciting that EP24.15 inhibition by siRNA can
alter isoproterenol signal transduction in cell culture. In the future,
3292 L.C. Russo et al. / FEBS Letters 586 (2012) 3287–3292in vivo studies should be conducted to evaluate the effects of
EP24.15 siRNA inhibition on the physiology of the sympathetic
nervous system.
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